Transphorm, Inc.

2023 Q3 Form 10-Q Financial Statement

#000171576823000075 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.152M $3.311M
YoY Change -81.63% -92.23%
Cash & Equivalents $6.152M $3.311M
Short-Term Investments
Other Short-Term Assets $1.426M $1.184M
YoY Change -44.47% -61.5%
Inventory $9.776M $8.885M
Prepaid Expenses
Receivables $4.571M $6.915M
Other Receivables $0.00 $0.00
Total Short-Term Assets $21.93M $20.30M
YoY Change -53.0% -63.66%
LONG-TERM ASSETS
Property, Plant & Equipment $7.857M $7.957M
YoY Change 47.47% 261.85%
Goodwill $963.0K $994.0K
YoY Change -3.31% -5.87%
Intangibles
YoY Change
Long-Term Investments $0.00 $662.0K
YoY Change -100.0% 95.28%
Other Assets $652.0K $697.0K
YoY Change -16.84% 139.52%
Total Long-Term Assets $12.36M $13.42M
YoY Change 9.39% 70.39%
TOTAL ASSETS
Total Short-Term Assets $21.93M $20.30M
Total Long-Term Assets $12.36M $13.42M
Total Assets $34.29M $33.72M
YoY Change -40.83% -47.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.044M $3.801M
YoY Change -9.97% -18.68%
Accrued Expenses $2.154M $2.716M
YoY Change 15.62% 65.51%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0% -100.0%
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $8.339M $8.271M
YoY Change -55.65% -56.12%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $230.0K
YoY Change -100.0% -92.18%
Total Long-Term Liabilities $0.00 $230.0K
YoY Change -100.0% -92.18%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.339M $8.271M
Total Long-Term Liabilities $0.00 $230.0K
Total Liabilities $10.60M $10.89M
YoY Change -50.95% -50.02%
SHAREHOLDERS EQUITY
Retained Earnings -$229.4M -$222.3M
YoY Change 20.76% 20.82%
Common Stock $6.000K $6.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $23.69M $22.82M
YoY Change
Total Liabilities & Shareholders Equity $34.29M $33.72M
YoY Change -40.83% -47.1%

Cashflow Statement

Concept 2023 Q3 2023 Q2

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5353000 usd
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-393000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-393000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5746000 usd
CY2022Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
226000 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
150000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3311000 usd
CY2023Q2 us-gaap Derivative Liability Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrent
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6915000 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4396000 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
8885000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
8406000 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1184000 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1859000 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
20295000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
30688000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7957000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7890000 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2863000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3033000 usd
CY2023Q2 us-gaap Goodwill
Goodwill
994000 usd
CY2023Q1 us-gaap Goodwill
Goodwill
1079000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
247000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
321000 usd
CY2023Q2 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
662000 usd
CY2023Q1 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
715000 usd
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
697000 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
726000 usd
CY2023Q2 us-gaap Assets
Assets
33715000 usd
CY2023Q1 us-gaap Assets
Assets
44452000 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6517000 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7895000 usd
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
0 usd
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
180000 usd
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1228000 usd
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1458000 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
526000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
404000 usd
CY2023Q2 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
0 usd
CY2023Q1 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
12000000 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
8271000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
21937000 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2390000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2670000 usd
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
230000 usd
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
230000 usd
CY2023Q2 us-gaap Liabilities
Liabilities
10891000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
24837000 usd
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59374057 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59374057 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
57047013 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
57047013 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
6000 usd
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
6000 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
247027000 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
230272000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-222295000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-209236000 usd
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1914000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1427000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
22824000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
19615000 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
33715000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44452000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5883000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5156000 usd
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
3795000 usd
CY2022Q2 us-gaap Cost Of Revenue
CostOfRevenue
4050000 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
2088000 usd
CY2022Q2 us-gaap Gross Profit
GrossProfit
1106000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2869000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1740000 usd
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1482000 usd
CY2022Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1083000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4516000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3317000 usd
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
8867000 usd
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
6140000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6779000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5034000 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
8000 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
182000 usd
CY2023Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-860000 usd
CY2022Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-582000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
200000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
445000 usd
CY2023Q2 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-7447000 usd
CY2022Q2 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-5353000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7447000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5353000 usd
CY2023Q2 tgan Deemed Dividend Related To Warrant Modification And Issuance Of Inducement Warrants
DeemedDividendRelatedToWarrantModificationAndIssuanceOfInducementWarrants
5612000 usd
CY2022Q2 tgan Deemed Dividend Related To Warrant Modification And Issuance Of Inducement Warrants
DeemedDividendRelatedToWarrantModificationAndIssuanceOfInducementWarrants
0 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13059000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-13059000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5353000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5353000 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59264378 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59264378 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54404830 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54404830 shares
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7447000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-487000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-487000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7934000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
19615000 usd
CY2023Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1000 usd
CY2023Q2 tgan Stock Issued During Period Value Warrant Exercises And Deemed Dividend
StockIssuedDuringPeriodValueWarrantExercisesAndDeemedDividend
7167000 usd
CY2023Q2 tgan Stock Issued During Period Deemed Dividend Related To Issuance Of Inducement Warrants Value
StockIssuedDuringPeriodDeemedDividendRelatedToIssuanceOfInducementWarrantsValue
0 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1974000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2003000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-487000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7447000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
22824000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
31361000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
20000 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15720000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
583000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5353000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
41938000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7447000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5353000 usd
CY2023Q2 us-gaap Inventory Write Down
InventoryWriteDown
2000 usd
CY2022Q2 us-gaap Inventory Write Down
InventoryWriteDown
37000 usd
CY2023Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
270000 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
131000 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
2003000 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
583000 usd
CY2023Q2 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
0 usd
CY2022Q2 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
2000 usd
CY2023Q2 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
48000 usd
CY2022Q2 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
100000 usd
CY2023Q2 tgan Gain Loss On Joint Ventures
GainLossOnJointVentures
-860000 usd
CY2022Q2 tgan Gain Loss On Joint Ventures
GainLossOnJointVentures
-582000 usd
CY2023Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-124000 usd
CY2022Q2 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
0 usd
CY2023Q2 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2519000 usd
CY2022Q2 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
645000 usd
CY2023Q2 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
481000 usd
CY2022Q2 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
670000 usd
CY2023Q2 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-670000 usd
CY2022Q2 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
604000 usd
CY2023Q2 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-29000 usd
CY2022Q2 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
28000 usd
CY2023Q2 tgan Increase Decrease In Accounts Payable Accrued Liabilities And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities
-2017000 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-30600000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7400000 usd
CY2022Q2 tgan Increase Decrease In Accounts Payable Accrued Liabilities And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities
1086000 usd
CY2023Q2 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 usd
CY2022Q2 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
8000 usd
CY2023Q2 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-230000 usd
CY2022Q2 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-51000 usd
CY2023Q2 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-120000 usd
CY2022Q2 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-136000 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8773000 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4913000 usd
CY2023Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 usd
CY2022Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
723000 usd
CY2023Q2 us-gaap Proceeds From Sales Of Assets Investing Activities
ProceedsFromSalesOfAssetsInvestingActivities
48000 usd
CY2022Q2 us-gaap Proceeds From Sales Of Assets Investing Activities
ProceedsFromSalesOfAssetsInvestingActivities
100000 usd
CY2023Q2 us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
807000 usd
CY2022Q2 us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
778000 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-759000 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1401000 usd
CY2023Q2 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
CY2022Q2 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
20000 usd
CY2023Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2000000 usd
CY2022Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
16000000 usd
CY2023Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
122000 usd
CY2022Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
280000 usd
CY2023Q2 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1000 usd
CY2022Q2 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0 usd
CY2023Q2 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
7263000 usd
CY2022Q2 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
CY2023Q2 us-gaap Repayments Of Debt
RepaymentsOfDebt
12000000 usd
CY2022Q2 us-gaap Repayments Of Debt
RepaymentsOfDebt
0 usd
CY2023Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2860000 usd
CY2022Q2 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15740000 usd
CY2023Q2 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-324000 usd
CY2022Q2 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-248000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12716000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9178000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16027000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33435000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3311000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42613000 usd
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
0 usd
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
500000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43113000 usd
CY2023Q2 us-gaap Interest Paid Net
InterestPaidNet
188000 usd
CY2022Q2 us-gaap Interest Paid Net
InterestPaidNet
180000 usd
CY2023Q2 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
342000 usd
CY2022Q2 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 usd
CY2023Q2 tgan Stock Warrant Exercise And Deemed Dividend Related To Warrant Modification
StockWarrantExerciseAndDeemedDividendRelatedToWarrantModification
753000 usd
CY2022Q2 tgan Stock Warrant Exercise And Deemed Dividend Related To Warrant Modification
StockWarrantExerciseAndDeemedDividendRelatedToWarrantModification
0 usd
CY2023Q2 tgan Deemed Dividend Related To Issuance Of Inducement Warrants
DeemedDividendRelatedToIssuanceOfInducementWarrants
4858000 usd
CY2022Q2 tgan Deemed Dividend Related To Issuance Of Inducement Warrants
DeemedDividendRelatedToIssuanceOfInducementWarrants
0 usd
CY2023Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2022Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3598000 usd
CY2023Q2 tgan Working Capital
WorkingCapital
12000000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7447000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5353000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13059000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-13059000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5353000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5353000 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59264378 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59264378 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54404830 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54404830 shares
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7948906 shares
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7127861 shares
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5883000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5156000 usd
CY2023Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
4785000 usd
CY2023Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
5167000 usd
CY2023Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2078000 usd
CY2023Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1719000 usd
CY2023Q2 tgan Inventory Sub Assembly Net Of Reserves
InventorySubAssemblyNetOfReserves
1145000 usd
CY2023Q1 tgan Inventory Sub Assembly Net Of Reserves
InventorySubAssemblyNetOfReserves
809000 usd
CY2023Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
877000 usd
CY2023Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
711000 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
8885000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
8406000 usd
CY2023Q2 us-gaap Inventory Write Down
InventoryWriteDown
2000 usd
CY2022Q2 us-gaap Inventory Write Down
InventoryWriteDown
40000.00 usd
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
23484000 usd
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
23601000 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15527000 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15711000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7957000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7890000 usd
CY2022Q2 us-gaap Depreciation
Depreciation
200000 usd
CY2023Q2 us-gaap Depreciation
Depreciation
200000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
5224000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4803000 usd
CY2023Q2 tgan Finite Lived Intangible Assets Accumulated Change In Foreign Exchange Rate
FiniteLivedIntangibleAssetsAccumulatedChangeInForeignExchangeRate
174000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
247000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
5224000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4729000 usd
CY2023Q1 tgan Finite Lived Intangible Assets Accumulated Change In Foreign Exchange Rate
FiniteLivedIntangibleAssetsAccumulatedChangeInForeignExchangeRate
174000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
321000 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
100000 usd
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
100000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
222000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
25000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
247000 usd
CY2022Q1 us-gaap Goodwill
Goodwill
1180000 usd
CY2023 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-101000 usd
CY2023Q1 us-gaap Goodwill
Goodwill
1079000 usd
CY2023Q2 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-85000 usd
CY2023Q2 us-gaap Goodwill
Goodwill
994000 usd
CY2023Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3801000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2781000 usd
CY2023Q2 tgan Accrued Manufacturing Production Costs Current
AccruedManufacturingProductionCostsCurrent
561000 usd
CY2023Q1 tgan Accrued Manufacturing Production Costs Current
AccruedManufacturingProductionCostsCurrent
506000 usd
CY2023Q2 tgan Accrued Legal Fees Current
AccruedLegalFeesCurrent
702000 usd
CY2023Q1 tgan Accrued Legal Fees Current
AccruedLegalFeesCurrent
596000 usd
CY2023Q2 tgan Accrued Audit Fees Current
AccruedAuditFeesCurrent
525000 usd
CY2023Q1 tgan Accrued Audit Fees Current
AccruedAuditFeesCurrent
318000 usd
CY2023Q2 tgan Accrued Consulting Fees Current
AccruedConsultingFeesCurrent
326000 usd
CY2023Q1 tgan Accrued Consulting Fees Current
AccruedConsultingFeesCurrent
256000 usd
CY2023Q2 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
63000 usd
CY2023Q1 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
0 usd
CY2023Q2 us-gaap Deposit Liability Current
DepositLiabilityCurrent
0 usd
CY2023Q1 us-gaap Deposit Liability Current
DepositLiabilityCurrent
2950000 usd
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
539000 usd
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
488000 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2716000 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5114000 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6517000 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7895000 usd
CY2021Q3 tgan Variable Interest Entity Maximum Loss Exposure Term
VariableInterestEntityMaximumLossExposureTerm
P3Y
CY2023Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
8000 usd
CY2022Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
200000 usd
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59374057 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59374057 shares
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 tgan Common Stock Voting Rights Number
CommonStockVotingRightsNumber
1 vote
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
13576678 shares
CY2023Q2 tgan Beneficial Ownership Percentage
BeneficialOwnershipPercentage
0.0999
CY2023Q2 tgan Increase In Beneficial Ownership Effectivity Notice Period
IncreaseInBeneficialOwnershipEffectivityNoticePeriod
P61D
CY2023Q2 tgan Registration Rights Agreement Filing Period
RegistrationRightsAgreementFilingPeriod
P30D
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4027929 shares
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3323966 shares
CY2023Q2 tgan Class Of Warrant Or Right Warrants Issued
ClassOfWarrantOrRightWarrantsIssued
2519811 shares
CY2023Q2 tgan Class Of Warrant Or Right Warrants Exercised
ClassOfWarrantOrRightWarrantsExercised
1815848 shares
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4027929 shares
CY2023Q2 us-gaap Share Based Goods And Nonemployee Services Transaction Modification Of Terms Incremental Compensation Cost
ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost
500000 usd
CY2023Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-100000 usd
CY2023Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
100000 usd
CY2023Q2 us-gaap Derivative Assets
DerivativeAssets
0 usd
CY2022Q2 us-gaap Derivative Assets
DerivativeAssets
0 usd
CY2022Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
0 usd
CY2023Q2 us-gaap Derivative Instruments Not Designated As Hedging Instruments Liability At Fair Value
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
124000 usd
CY2023Q2 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
124000 usd
CY2023Q2 us-gaap Derivative Liability Fair Value Gross Asset
DerivativeLiabilityFairValueGrossAsset
0 usd
CY2023Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
124000 usd
CY2023Q2 us-gaap Derivative Instruments Not Designated As Hedging Instruments Liability At Fair Value
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
124000 usd
CY2023Q2 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
124000 usd
CY2023Q2 us-gaap Derivative Liability Fair Value Gross Asset
DerivativeLiabilityFairValueGrossAsset
0 usd
CY2023Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
124000 usd

Files In Submission

Name View Source Status
tgan-20230630_cal.xml Edgar Link unprocessable
0001715768-23-000075-index-headers.html Edgar Link pending
0001715768-23-000075-index.html Edgar Link pending
0001715768-23-000075.txt Edgar Link pending
0001715768-23-000075-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tgan-20230630.htm Edgar Link pending
tgan-20230630.xsd Edgar Link pending
tgan-20230630_g1.jpg Edgar Link pending
tganex31106302023ceocertif.htm Edgar Link pending
tganex31206302023cfocertif.htm Edgar Link pending
tganex32106302023ceocfocer.htm Edgar Link pending
tgan-20230630_def.xml Edgar Link unprocessable
tgan-20230630_lab.xml Edgar Link unprocessable
tgan-20230630_pre.xml Edgar Link unprocessable
tgan-20230630_htm.xml Edgar Link completed